In Neuromyelitis Optica Spectrum Disorder (NMOSD), drugs like rozanolixizumab can rapidly reduce anti-AQP4 antibody titers and decrease the risk of acute attacks, with some drugs submitted for relevant indications in Europe and the US, potentially becoming new maintenance therapy options. This evidence concerns the gene AQP4 and neuromyelitis optica.